Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese SFDA Reorganization Creates “Good Opportunity” For Supplement Firms – NPA

This article was originally published in PharmAsia News

Executive Summary

The reorganization of China's State FDA should create a "really good opportunity" for the dietary supplement industry, says Jeff Crowther, director of the Natural Products Association's office in China

You may also be interested in...

China’s State FDA Now Under Ministry Of Health

According to China State Council's new institutional restructuring plan, China's State FDA now reports directly to the Ministry of Health instead of the Council. The ministry will take over the policy- and regulation-forming role while SFDA will focus on implementation and execution. MOH will set food safety standards and drug laws, as well as establish a national system for basic medicine. SFDA will handle food sanitation approval, supervise consumer food safety of the food and beverage industry, and oversee drug safety throughout R&D, approvals, production and distribution. (Click here for more - Chinese Language)

Import Safety Agreement Further Entwines FDA/China Regulatory Process

Chinese manufacturers of certain drugs or active pharmaceutical ingredients selected by FDA will have to meet new registration standards as part of a memorandum of understanding signed Dec. 11 in Beijing by HHS, FDA and China's State Food and Drug Administration

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts